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Abstract
Background: The relationship between bed days and benzodiazepine prescription (BDZ) in
Western countries is inconclusive, and no hospital-based report has documented this phenomenon
in Japan. This study was done to assess the association between bed days and BDZ in a Japanese
hospital.
Methods: 21,489 adult patients (55.1% men, mean age 59.9 years old) hospitalized between April,
2005 and December, 2006 were enrolled in the study. Patient age, sex, ICD-10 diagnosis,
prescription profile, and days of hospital stay were assessed in 13 non-psychiatric departments
using a computer ordering system. Patients prescribed a benzodiazepine during hospitalization
were defined as positive.
Results: Of the total sample, 19.9% were allocated to the benzodiazepine (+) group. Female sex
and older age were significant factors associated with benzodiazepine prescription. The median
number of bed days was 13, and the likelihood of BDZ significantly increased with the number of
bed days, even after controlling for the effects of age, gender, and ICD-10 diagnosis. For example,
when the analysis was limited to patients with 50 bed days or longer, the percentage of BDZ
(32.7%) was equivalent to that of a report from France.
Conclusion: Irrespective of department or disease, patients prescribed benzodiazepine during
their hospital stay tended to have a higher number of bed days in the hospital. The difference in the
prevalence of BDZ between this study and previous Western studies might be attributed to the
relatively short length of hospital stay in this study. Because BDZs are often reported to be
prescribed to hospitalized patients without appropriate documentation for the indications for use,
it is important to monitor the rational for prescriptions of benzodiazepine carefully, for both clinical
and economical reasons.
Background
Benzodiazepines are among the most commonly used
classes of medication because of their multiple therapeu-
tic actions as anxiolytics, sedative hypnotics, anticonvul-
sants, and muscle relaxants [1,2]. However, it has been
reported that benzodiazepines are often prescribed in
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hospitals and for surgical patients in the absence of appro-
priate documentation of the indications for their use [3-
7]. Benzodiazepine use during hospital stays is an impor-
tant factor in the excessive long-term use of these drugs
and can be harmful especially to the elderly, who have
increased risks of falls and fractures [8,9] and cognitive
and memory changes [10,11] that could dramatically
decrease their quality of life. Thus it is important to pre-
scribe benzodiazepines for inpatients appropriately, con-
sidering the balance of benefit and risk.
Although the relationship between bed days and benzodi-
azepine prescription has been studied in several Western
countries, the number of subjects was relatively small
(<1,000) [12-16], the analysis was limited to the elderly
[12,13,17] or to those at limited departments [12,14,15],
or the diagnostic information was not controlled for in
the analyses [4,18]. The findings are inconsistent among
such Western studies, and no empirical study has been
conducted on these issues in Japanese hospitals.
Thus we quantitatively clarified the relationship between
benzodiazepine prescription and length of hospital stay at
our Japanese university hospital, taking into considera-
tion the effects of important clinical factors; patient age,
sex, and diagnosis; in this study.
Methods
Study setting
The study population consisted of 21,489 adult inpatients
aged 18 years or older, who were admitted to 13 depart-
ments at Teikyo University Hospital, Tokyo, Japan: inter-
nal medicine, neurology, general surgery, neurosurgery,
cardiac surgery, orthopedics, plastic surgery, obstetrics
and gynecology, ophthalmology, otorhinolaryngology,
dermatology, urology, and emergency medicine. The hos-
pital is a tertiary care hospital with 1,154 hospital beds,
and approximately 60,000 outpatients visit each year [19-
22]. Of the 15 departments in the hospital, the Depart-
ment of Psychiatry was excluded because of the study pur-
pose, and Pediatrics was excluded because the study was
targeted at adults. All clinical activities, including prescrip-
tions and length and monetary cost of hospital stay, are
recorded in a computer ordering system (COS) at the hos-
pital. To create a patient-based data set, data syntheses
were conducted using Access 2000 and a SQL server 2000
(Microsoft, Inc., Japan). Diagnoses were based on ICD-10
categories, and physicians-in-charge entered the three-
digit ICD-10 codes. The diagnostic categories analyzed
were as follows: infectious diseases (A00-B99), neoplasms
(C00-D48), blood diseases (D50-D89), endocrine dis-
eases (E00-E90), nervous system diseases (G00-G99), eye
diseases (H00-H59), ear diseases (H60-H95), circulatory
diseases (I00-I99), respiratory diseases (J00-J99), diges-
tive diseases (K00-K93), skin diseases (L00-L99), muscu-
loskeletal diseases (M00-M99), genitourinary diseases
(N00-N99), obstetrical diseases (O00-O99), other symp-
toms and signs (R00-R99), and other diseases (remaining
categories). The study period was from 1 April 2005 to 31
December 2006.
The study was carried out in accordance with the Declara-
tion of Helsinki (1981) of the World Medical Association.
The study protocol was approved by the Ethics Committee
of Teikyo University School of Medicine.
Benzodiazepine prescription
Referring to the Anatomical Therapeutic Chemical Classi-
fication System [23], index groups included N05BA (ben-
zodiazepine derivatives in anxiolytics, 01 = diazepam, 02
= medazepam, 04 = oxazolam, 06 = lorazepam, 08 = bro-
mazepam, 12 = alprazolam, 18 = ethyl loflazepate, 19 =
etizolam, 21 = clothiazepam, 22 = cloxazolam, 23 =
tofisopam), N05CD (benzodiazepine derivatives in hyp-
notics and sedatives, 01 = flurazepam, 02 = nitrazepam,
03 = flunitrazepam, 05 = triazolam, 06 = lormetazepam,
09 = brotiazepam, 10 = quazepam), and N5CM (other
hypnotics and sedatives, rilmazafone hydrochloride).
Information was obtained regarding benzodiazepine pre-
scription during the hospital stay. Of the 8,017,817 tab-
lets and capsules prescribed in the study period, the total
number of benzodiazepines was 349,449 (4.4%). The
most frequently prescribed benzodiazepines, in descend-
ing order, were brotiazepam (n = 74,408), etizolam (n =
58,385), triazolam (n = 39,545), lorazepam (n = 28,056),
flunitrazepam (n = 25,026), nitrazepam (n = 23,820),
diazepam (n = 19,000), alprazolam (n = 17,515), ethyl
loflazepate (n = 17,208), and bromazepam (n = 12,351).
The patients were divided into two groups depending on
the prescription of benzodiazepines: the benzodiazepine
(+) group consisted of those with any prescription for
benzodiazepines during their hospital stay; the benzodi-
azepine (-) group had no benzodiazepine prescription
during the hospital stay.
Data analysis
Data were analyzed using the SAS statistical package [24],
and P < 0.05, all two-tailed, was deemed to be statistically
significant. Adjustment for age (continuous variable), sex
(women or men), and ICD-10 diagnosis (16 categories)
was done by multiple logistic regression analysis. The
odds ratio for benzodiazepine prescription was estimated
according to the distribution of bed days (4 days for the
25th percentile, 13 days for the median, and 49 days for
the 75th percentile). The data on bed days were divided
into four ordinal categories because their distribution was
not assumed to be normal (P = 0.010 for Kolmogorov-
Smirnov test).BioPsychoSocial Medicine 2009, 3:10 http://www.bpsmedicine.com/content/3/1/10
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Results
The number of inpatients prescribed benzodiazepine was
4,282 (19.9%). The percentage of patients prescribed ben-
zodiazepine was significantly higher for women than for
men, and the percentage increased with age (Table 1).
When divided into 10-year age categories, the percentage
of patients prescribed benzodiazepine tended to increase
with age, both for men and women (Figure 1). The per-
centage of patients prescribed benzodiazepine by ICD-10
diagnosis is shown in Figure 2. When the specific three-
digit codes of ICD-10 were analyzed (n > 100), benzodi-
azepine prescription was most common for patients diag-
nosed with chronic renal failure (N18, 31.3%), followed
by heart failure (I50, 29.3%), acute myocardial infarction
(I21, 28.9%), malignant neoplasm of the liver and intra-
hepatic bile ducts (C22, 28.0%), post-procedural disor-
ders of the nervous system (G97, 28.0%), malignant
neoplasm of the bronchus and lung (C34, 27.7%), non-
insulin-dependent diabetes mellitus (E11, 25.0%), and
malignant neoplasm of the bladder (C67, 22.2%). The
percentage of patients prescribed benzodiazepine by
department is shown in Figure 3. It was highest at the
department of neurology (35.8%), followed by cardiac
surgery (35.8%), orthopaedics (26.3%), general surgery
(24.1%), internal medicine (23.7%), neurosurgery
(20.3%), and dermatology (20.2%).
The arithmetic mean (standard deviation) for bed days
was 29.6 (35.7) days, the geometric mean 13.9 (4.0) days,
and the median value (range) was 13 (1-254) days for the
total sample. The percentage of patients prescribed benzo-
diazepine tended to increase with the number of bed days.
According to the results of multiple logistic regression
analysis, benzodiazepine prescription was significantly
associated with bed days, even after adjusting for the
effects of the three independent variables; age, gender,
and ICD-10 diagnosis (Table 1).
Discussion
One-fifth of the inpatients had been prescribed benzodi-
azepines during their hospital stay. The elderly (≥ 65
years) were more likely to have a benzodiazepine pre-
scribed compared to the non-elderly, as were women
compared to men. Although the percentage of benzodi-
azepine prescribed varied by department and ICD-10
diagnosis, it was significantly associated with a higher
number of bed days, even after adjusting for the effects of
age, gender, and ICD-10 diagnosis.
The percentage for benzodiazepine prescription was
higher than was found for outpatients in our previous
study (12%) [19,20], but was rather low when compared
with Western studies of inpatients, which have reported
prevalences of 33-45% [3,15,18]. A possible explanation
for this difference is the relatively short length hospitaliza-
tion in our study. When the analysis was limited to those
with ≥ 50 bed days, the percentage given benzodiazepine
prescriptions was equivalent to that in a report from
France (33%) [15]. However, this fact does not necessarily
weaken the generalizability of our results to Japanese
inpatients, because the arithmetic mean of bed days is
reported to be 20 days for Japanese general hospitals and
36 days for all Japanese hospitals according to a national
survey by the Japanese Ministry of Health, Labor, and
Welfare [25]. The average number of bed days in our hos-
pital (= 30 days) was typical of Japanese hospitals.
Table 1: Odds ratios (95% confidence intervals, C.I.) for benzodiazepine prescription (BDZ) to 21,489 inpatients
N %BDZ Odds ratio (95%C.I.)a
Age, years
18 to 44 5,023 14.0 ---
45 to 64 6,028 19.8 1.51 (1.37, 1.68)
65 to 74 5,355 22.7 1.80 (1.63, 2.00)
75 or older 5,083 23.0 1.83 (1.65, 2.03)
Sex
Male 11,844 18.6 ---
Female 9,645 21.6 1.21 (1.13, 1.29)
Number of bed days
4 or shorter 5,938 9.1 ---
5 to 13 5,258 16.5 1.98 (1.76, 2.22)
14 to 49 4,917 22.8 2.96 (2.65, 3.31)
50 or longer 5,376 32.7 4.86 (4.37, 5.40)
aThe variables age and sex from logistic regression analysis were used to estimate a crude odds ratio for benzodiazepine prescription.
For the number of bed days, multiple logistic regression analysis was used to estimate the odds ratio for benzodiazepine use, adjusted by age, sex, 
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Another possible explanation is the Japanese unwilling-
ness to admit to psychiatric symptoms. The Japanese peo-
ple have high thresholds for not visiting psychiatric clinics
[26] and tend to complain of somatic symptoms, even if
they suffer from mental illnesses such as depression
[27,28]. There may have been some patients in our study
for whom psychological complaints were masked and
who were followed up without anti-psychotropic regi-
mens. It is reasonable that specific diseases such as musc-
uloskeletal and nervous system diseases and the
corresponding departments of neurology and orthopedics
had high prevalences of benzodiazepine prescription
because increased muscle tension is often accompanied
by psychological distress, and benzodiazepines have a
therapeutic effect as a muscle relaxant [1,2,29]. It is also
reasonable that patients hospitalized in the department of
cardiac surgery had a higher prevalence of benzodiazepine
prescription because of cardiovascular symptoms due to
their disease and the extremely anxious situation before
heart surgery [30]. Although these implications are incon-
clusive, extensive intervention would be needed for inpa-
tients with such disease conditions and further study
needs to be done to assess their psychological distress and
the degree of patient satisfaction. Through such assess-
ment, important factors may be found for how to shorten
the number of bed days for such patients.
Because an increased number of bed days has been
reported to be closely related to the anxiety of inpatients
with a wide rage of general medical disorders [10], it is
possible that those staying at a hospital for a long time are
likely to be anxious about their disease condition and that
such worries may lead the patient seeking to use benzodi-
azepines. This was a cross-sectional study, and it is also
possible that the side effects of benzodiazepines may con-
tribute to extended hospital stays [31]. There may be
room for reducing medical costs by targeting patients who
have been hospitalized for a long time [32,33]. Although
the data are preliminary and not listed in the table, the
percentage prescribed benzodiazepine was 10.2% for
patients with hospital expenses of less than 2,000 US$ (n
= 5,562), whereas it was 32.0% for those with expenses of
8,500 US$ or more (n = 5,169). For example, it may be
good to routinely screen the mental condition of inpa-
tients using a simple questionnaire before prescribing
benzodiazepines and to use a consultation-liaison service
with psychiatric specialists for the treatment of patients
prescribed benzodiazepines [34]. Particularly, the elderly
should be targeted because of the high prevalence of ben-
zodiazepine prescription to those aged = 65 years. Possi-
ble side effects of benzodiazepines, such as memory loss
and increased risks for falls and fractures, are also issues of
the elderly [8,9,11,13,35].
Before making conclusions, we must mention several
study limitations. First, this was a database study, and the
specific reasons for prescribing benzodiazepine were
often unclear. For example, it is possible that some inpa-
tients in the department of surgery may have been pre-
scribed benzodiazepine as a pre-medication. However, a
close relationship between benzodiazepine prescription
and bed days was observed in non-surgical departments
as well. Future tasks would be to gather information on
the use of benzodiazepines from both inpatients and the
physician-in-charge. Second, a cross-sectional study
design prevented us from coming to conclusions regard-
ing causal relationships between benzodiazepine pre-
scription and the number of bed days. The use of
benzodiazepine might be a simple marker for, rather than
a cause of, prolonged hospitalization. That is, the chance
of benzodiazepine prescription would be higher for
patients with longer hospital stays because the percentage
of benzodiazepine use increased with increased bed days.
However, we can at least state that the monitoring of ben-
zodiazepine prescription is important in hospitals,
whether or not benzodiazepine prescriptions are a cause
or a consequence. For those who have already been in the
hospital for long time, the continuing appropriateness of
benzodiazepine prescription should be checked. Finally,
our findings cannot be compared with those at other
Age- and gender-specific percentages of patients prescribed  benzodiazepines Figure 1
Age- and gender-specific percentages of patients pre-
scribed benzodiazepines. The number of male inpatients 
in each age category was as follows: 18--24 yr (n = 391), 25--
34 yr (n = 827), 35--44 yr (n = 1017), 45--54 yr (n = 1119), 
55--64 yr (n = 2547), 65--74 yr (n = 3285), 75--84 yr (n = 
2207), and ≥ 85 yr (n = 451). The number of female inpa-
tients in each age category was as follows: 18--24 yr (n = 
399), 25--34 yr (n = 1241), 35--44 yr (n = 1148), 45--54 yr (n 
= 843), 55--64 yr (n = 1519), 65--74 yr (n = 2070), 75--84 yr 
(n = 1807), and ≥ 85 yr (n = 618). * P < 0.05 between sexes 
(chi-square test, two-tailed, Bonferroni multiple compari-
sons).
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medical institutions in Japan because, to our knowledge,
this is the first study of its type in Japan. The hospital of
the study is a university teaching hospital that has hun-
dreds of physicians who work in all general departments
that offer outpatient clinics; thus, any tendency in pre-
scribing practices might reflect the effects of Japanese edu-
cational conferences and the advice of supervisors, rather
than individual prescribing preferences [36]. To general-
ize our conclusions requires further studies at other Japa-
nese institutions, as well as hospitals in other countries.
Conclusion
Despite these limitations, our findings have valuable
implications. This is the first study to report data on inpa-
tients that are relevant to the discussion of the use of ben-
zodiazepines in Japanese hospitals. We found that the
Percentage of patients prescribed benzodiazepines according to ICD-10 category Figure 2
Percentage of patients prescribed benzodiazepines according to ICD-10 category. Abbreviations of ICD-10 cate-
gories are as follows; "Musc" for musculoskeletal diseases (n = 859), "Nerv" for nervous system diseases (n = 931), "Ear" for 
ear diseases (n = 526), "Blood" for blood diseases (n = 126), "Endo" for endocrine diseases (n = 699), "Neo" for neoplasms (n 
= 5,321), "Circ" for circulatory diseases (n = 3,221), "Symp" for other symptoms and signs (n = 298), "Infe" for infectious dis-
eases (n = 550), "Other" for other diseases (n = 1,626), "Resp" for respiratory diseases (n = 1,188), "Dige" for digestive dis-
eases (n = 1,883), "Geni" for genitourinary diseases (n = 1,141), "Skin" for skin diseases (n = 235), "Eye" for eye diseases (n = 
2,094), and "Obst" for obstetrical diseases (n = 791).
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Percentage of patients prescribed benzodiazepines by departments Figure 3
Percentage of patients prescribed benzodiazepines by departments. Abbreviations of departments are as follows; 
"Nuerol" for neurology (n = 520), "Cardiosurg" for cardiac surgery (n = 243), "Orthop" for orthopedics (n = 1,378), "Surg" for 
general surgery (n = 3,394), "Intern" for internal medicine (n = 6,811), "Neurosurg" for neurosurgery (n = 901), "Dermatol" for 
dermatology (n = 258), "Otolaryng" for otorhinolaryngology (n = 1,371), "Plastic" for plastic surgery (n = 430), "Emerg" for 
emergency medicine (n = 752), "Urol" for urology (n = 1,760), "Gynecol" for obstetrics and gynecology (n = 1,532), and "Oph-
thal" for ophthalmology (n = 2,139).
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percentage of benzodiazepine prescriptions increased
with the number of bed days and that patients prescribed
benzodiazepines generally stayed for a longer period than
those who were not prescribed benzodiazepines. Based
on the finding of a high percentage of benzodiazepine
prescription to elderly inpatients, pharmacological treat-
ment should be considered carefully using evidence-based
clinical guidelines; alternatively, physicians might refer
patients to psychiatrists or specialists in mental health.
Further studies are needed to determine the precise
cause(s) of the high level of benzodiazepine prescription
in Japanese hospitals.
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